Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study

Authors: Ada Tosovic, Anne-Greth Bondeson, Lennart Bondeson, Ulla-Britt Ericsson, Jonas Manjer

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The issue of a potential association between thyroid conditions/hormones and breast cancer has been studied extensively during the last decades but the results have been inconclusive and almost no studies have investigated breast cancer aggressiveness. We have previously found a positive association between prospectively measured levels of triiodothyronine (T3) and breast cancer incidence as well as breast cancer mortality. We now investigated prediagnostic T3 levels in relation to specific prognostic factors in breast cancer.

Methods

The Malmö Preventive Project is a population-based prospective cohort including 2185 women in whom T3 levels were measured at baseline. That is, total T3 levels were measured before a potential diagnosis of breast cancer. Mean follow-up was 23.3 years and 149 women in the study population were diagnosed with invasive breast cancer. Tumours were classified according to selected prognostic factors of breast cancer; i.e. grade, tumour size, lymph node metastasis, and hormonal receptor status. T3 was handled both as tertiles and as a continuous variable. A Cox’s proportional hazards analysis yielded hazard ratios with 95% confidence intervals. All analyses were also restricted to postmenopausal women.

Results

Overall there was a statistically significant association between T3 and “all” breast cancers. The adjusted Hazard Ratio (HR) in the third tertile, as compared to the first, was (1.61:1.07-2.43). There was a statistically significant positive association between the third T3 tertile and large tumours, i.e. > 20 mm, (3.17:1.20-8.36) and the occurrence of lymph node metastases, (4.53:1.60-12.83). Other prognostic factors positively associated with T3 were negative oestrogen receptor (ER) status, (3.52:1.32-9.41) and negative progesterone receptor (PGR) status, (3.52:1.42-8.75). The analyses of T3 as a continuous variable and analysis restricted to postmenopausal women, confirmed the results but also showed an association with smaller tumours and in postmenopausal women a contemporary association with negative lymph nodes.

Conclusions

This prospective study of serum T3 levels in relation to breast cancer aggressiveness is the first of its kind. We found statistically significant positive associations between higher prediagnostic T3 levels and larger tumours, occurrence of lymph node metastases, and negative ER and PGR status.
Literature
1.
go back to reference Sarlis NJ, Gourgiotis L, Pucino F, Tolis GJ: Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones (Athens). 2002, 1: 35-41.CrossRef Sarlis NJ, Gourgiotis L, Pucino F, Tolis GJ: Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones (Athens). 2002, 1: 35-41.CrossRef
2.
go back to reference Goldman MB: Thyroid diseases and breast cancer. Epidemiol Rev. 1990, 12: 16-28.PubMed Goldman MB: Thyroid diseases and breast cancer. Epidemiol Rev. 1990, 12: 16-28.PubMed
3.
4.
go back to reference Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, Pinchera A, Giani C: Favourable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest. 2007, 30: 734-738.CrossRefPubMed Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, Pinchera A, Giani C: Favourable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest. 2007, 30: 734-738.CrossRefPubMed
5.
go back to reference Jiskra J, Barkmanova J, Limanova Z, La’nska V, Smutek D, Potlukova E, Antosova M: Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep. 2007, 18: 1603-1611.PubMed Jiskra J, Barkmanova J, Limanova Z, La’nska V, Smutek D, Potlukova E, Antosova M: Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep. 2007, 18: 1603-1611.PubMed
6.
go back to reference Farahati J, Roggenbuck D, Gilman E, Schütte M, Jagminaite E, Seyed Zakavi R, Löning T, Heissen E: Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer. Clin Chem Lab Med. 2012, 50: 709-714.CrossRefPubMed Farahati J, Roggenbuck D, Gilman E, Schütte M, Jagminaite E, Seyed Zakavi R, Löning T, Heissen E: Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer. Clin Chem Lab Med. 2012, 50: 709-714.CrossRefPubMed
7.
go back to reference Cengiz O, Bozkurt B, Unal B, Yildirim O, Karabeyoglu M, Eroglu A, Kocer B, Ulas M: The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol. 2004, 87: 19-25.CrossRefPubMed Cengiz O, Bozkurt B, Unal B, Yildirim O, Karabeyoglu M, Eroglu A, Kocer B, Ulas M: The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol. 2004, 87: 19-25.CrossRefPubMed
8.
go back to reference Lemaire M, Baugnet-Mahieu L: Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol. 1986, 22: 301-307.CrossRefPubMed Lemaire M, Baugnet-Mahieu L: Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol. 1986, 22: 301-307.CrossRefPubMed
9.
go back to reference Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J: Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res. 2010, 12: R33-CrossRefPubMedPubMedCentral Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J: Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res. 2010, 12: R33-CrossRefPubMedPubMedCentral
10.
go back to reference Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Malm J, Manjer J: Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer. 2012, 131: 2126-2133.CrossRefPubMed Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Malm J, Manjer J: Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer. 2012, 131: 2126-2133.CrossRefPubMed
11.
go back to reference Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Manjer J: Triiodothyronine levels in relation to mortality from breast cancer and all causes: a population-based prospective cohort study. Eur J Endocrinol. 2013, 168: 483-490.CrossRefPubMed Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Manjer J: Triiodothyronine levels in relation to mortality from breast cancer and all causes: a population-based prospective cohort study. Eur J Endocrinol. 2013, 168: 483-490.CrossRefPubMed
12.
go back to reference Manjer J, Berglund G, Bondesson L, Garne JP, Janzon L, Malina J: Breast cancer incidence in relation to smoking cessation. Breast Cancer Res Treat. 2000, 61: 121-129.CrossRefPubMed Manjer J, Berglund G, Bondesson L, Garne JP, Janzon L, Malina J: Breast cancer incidence in relation to smoking cessation. Breast Cancer Res Treat. 2000, 61: 121-129.CrossRefPubMed
13.
go back to reference Thorell JL, Larson SM: Radioimmunoassay and related techniques. 1978, Methodology and Clinical Applications Saint Louis: Mosby Thorell JL, Larson SM: Radioimmunoassay and related techniques. 1978, Methodology and Clinical Applications Saint Louis: Mosby
14.
go back to reference Almquist M, Anagnostaki L, Bondeson L, Bondeson AG, Borgquist S, Landberg G, Malina J, Malm J, Manjer J: Serum calcium and tumour aggressiveness in breast cancer. Eur J Cancer Prev. 2009, 18: 354-360.CrossRefPubMed Almquist M, Anagnostaki L, Bondeson L, Bondeson AG, Borgquist S, Landberg G, Malina J, Malm J, Manjer J: Serum calcium and tumour aggressiveness in breast cancer. Eur J Cancer Prev. 2009, 18: 354-360.CrossRefPubMed
15.
go back to reference Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410.CrossRefPubMed Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410.CrossRefPubMed
16.
go back to reference Michael B, Harvey S: Fast Facts – Breast Cancer. 2002, Oxford: Health Press Limited Michael B, Harvey S: Fast Facts – Breast Cancer. 2002, Oxford: Health Press Limited
17.
go back to reference Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L: Smoking associated with hormone receptor negative breast cancer. Int J Cancer. 2001, 91: 580-584.CrossRefPubMed Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L: Smoking associated with hormone receptor negative breast cancer. Int J Cancer. 2001, 91: 580-584.CrossRefPubMed
18.
go back to reference Garne JP: Invasive breast cancer in Malmo 1961-1992 – an epidemiological study. A PhD Thesis. 1996, Lund, Sweden: Department of Surgery, Lund University Garne JP: Invasive breast cancer in Malmo 1961-1992 – an epidemiological study. A PhD Thesis. 1996, Lund, Sweden: Department of Surgery, Lund University
19.
go back to reference Russell W, Harrison RF, Smith N, Darzy K, Shalet S, Weetman AP, Ross RJ: Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels. J Clin Endocrinol Metab. 2008, 93: 2300-2306.CrossRefPubMed Russell W, Harrison RF, Smith N, Darzy K, Shalet S, Weetman AP, Ross RJ: Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels. J Clin Endocrinol Metab. 2008, 93: 2300-2306.CrossRefPubMed
20.
go back to reference Andersen S, Pedersen KM, Bruun NH, Laurberg P: Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002, 87: 1068-1072.CrossRefPubMed Andersen S, Pedersen KM, Bruun NH, Laurberg P: Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002, 87: 1068-1072.CrossRefPubMed
21.
go back to reference Utiger RD: Estrogen, thyroxine binding in serum, and thyroxine therapy. N Engl J Med. 2001, 344: 1784-CrossRefPubMed Utiger RD: Estrogen, thyroxine binding in serum, and thyroxine therapy. N Engl J Med. 2001, 344: 1784-CrossRefPubMed
22.
go back to reference Martínez-Iglesias O, García-Silva S, Regadera J, Aranda A: Hypothyroidism Enhances Tumour Invasiveness and Metastasis Development. PLoS One. 2009, 4: e6428-CrossRefPubMedPubMedCentral Martínez-Iglesias O, García-Silva S, Regadera J, Aranda A: Hypothyroidism Enhances Tumour Invasiveness and Metastasis Development. PLoS One. 2009, 4: e6428-CrossRefPubMedPubMedCentral
23.
go back to reference Economidou F, Douka E, Tzanela M, Nanas S, Kotanidou A: Thyroid function during critical illness. Hormones. 2011, 10: 117-124.CrossRefPubMed Economidou F, Douka E, Tzanela M, Nanas S, Kotanidou A: Thyroid function during critical illness. Hormones. 2011, 10: 117-124.CrossRefPubMed
24.
go back to reference Saraiva PP, Figueiredo NB, Padovani CR, Bretani MM, Nogueira CR: Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res. 2005, 38: 761-765.CrossRefPubMed Saraiva PP, Figueiredo NB, Padovani CR, Bretani MM, Nogueira CR: Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res. 2005, 38: 761-765.CrossRefPubMed
25.
go back to reference Dinda S, Sanchez A, Moudgil V: Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene. 2002, 21: 761-768.CrossRefPubMed Dinda S, Sanchez A, Moudgil V: Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene. 2002, 21: 761-768.CrossRefPubMed
26.
go back to reference Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI: Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol. 2006, 17: 60-64.CrossRefPubMed Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI: Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol. 2006, 17: 60-64.CrossRefPubMed
27.
go back to reference Nogueira CR, Brentani MM: Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996, 59: 271-279.CrossRefPubMed Nogueira CR, Brentani MM: Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996, 59: 271-279.CrossRefPubMed
28.
go back to reference Hall LC, Salazar EP, Kane SR, Liu N: Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol. 2008, 109: 57-66.CrossRefPubMed Hall LC, Salazar EP, Kane SR, Liu N: Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol. 2008, 109: 57-66.CrossRefPubMed
29.
go back to reference Silva JM, Dominguez G, González-Sancho JM, Garcia JM, Silva J, Garcia-Andrade C, Navarro A, Muñoz A, Bonilla F: Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002, 21: 4307-4316.CrossRefPubMed Silva JM, Dominguez G, González-Sancho JM, Garcia JM, Silva J, Garcia-Andrade C, Navarro A, Muñoz A, Bonilla F: Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002, 21: 4307-4316.CrossRefPubMed
30.
go back to reference Ditsch N, Toth B, Himsl I, Lenhard M, Ochsenkühn R, Friese K, Mayr D, Jeschke U: Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer. Histol Histopathol. 2013, 28: 227-237.PubMed Ditsch N, Toth B, Himsl I, Lenhard M, Ochsenkühn R, Friese K, Mayr D, Jeschke U: Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer. Histol Histopathol. 2013, 28: 227-237.PubMed
31.
go back to reference van de Vijver M vBR, Devilee P, Cornelisse C, Peterse J, Nusse R: Amplification of the neu(c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often acccompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987, 7: 2019-2023.CrossRefPubMedPubMedCentral van de Vijver M vBR, Devilee P, Cornelisse C, Peterse J, Nusse R: Amplification of the neu(c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often acccompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987, 7: 2019-2023.CrossRefPubMedPubMedCentral
32.
go back to reference Moeller LC, Führer D: Thyroid hormones, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer. 2013, 20: R19-R29.CrossRefPubMed Moeller LC, Führer D: Thyroid hormones, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer. 2013, 20: R19-R29.CrossRefPubMed
33.
go back to reference Huang JBJG, Xing L, Jin LB, Xu CB, Xiong X, Li HY, Ren GS, Wu KN, Kong LQ: Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine. BMC Cancer. 2013, 13: 334-CrossRefPubMedPubMedCentral Huang JBJG, Xing L, Jin LB, Xu CB, Xiong X, Li HY, Ren GS, Wu KN, Kong LQ: Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine. BMC Cancer. 2013, 13: 334-CrossRefPubMedPubMedCentral
Metadata
Title
T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study
Authors
Ada Tosovic
Anne-Greth Bondeson
Lennart Bondeson
Ulla-Britt Ericsson
Jonas Manjer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-536

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine